Thermo Fisher expands Acros Organics range

Published: 16-Nov-2011
Ingredients

The Ultra Pure Inorganics portfolio is now 50% larger

Thermo Fisher Scientific, a world leader in serving science, has significantly expanded its Acros Organics Ultra Pure Inorganics products to meet increasing demand in high-technology industries and other chemistry applications.

This portfolio, which is now 50% larger, features new high-purity inorganic compounds with ultra-low metal contaminants, which are critical in specific high-technology applications such as petroleum refining, micro-electronics, energy and space technology, communications and other industries. This includes their use in the catalysis of reactions and crystal growth as well as the manufacture of photovoltaic materials, optical fibres and lasers. These extremely pure inorganics have trace-metal content of less than 100ppm to as low as 1ppm.

The Acros Organics Ultra Pure Inorganics line is featured in a brochure that provides full product descriptions, extended details of their potential uses, chemical purity information and product codes for easy ordering. The new brochure can be downloaded at www.acros.com.

  • Companies:
  • Thermo Fisher Scientific
See more

You may also like

Ingredients

Thermo Fisher Scientific launches next-generation Invitrogen TaqMan Cells-to-CT Express Kit with simplified, more sustainable workflow

Read more
With the Cells-to-CT Express Kit, researchers can measure relative gene expression while skipping the traditional RNA purification step when performing RT-qPCR

Trending Articles

  1. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Thermo Fisher Scientific launches next-generation Invitrogen TaqMan Cells-to-CT Express Kit with simplified, more sustainable workflow

With the Cells-to-CT Express Kit, researchers can measure relative gene expression while skipping the traditional RNA purification step when performing RT-qPCR
Ingredients

Multi-Attribute Method (MAM) for quality control in therapeutic proteins manufacturing

Therapeutic proteins are a unique class of large molecule drugs that have far more complex structures than the small molecule drugs
Ingredients

Thermo Fisher announces assays for oncology applications

The pan-clonality assays target multiple parts of the B- and T-cell immune receptors using a single reaction with ultra-high sensitivity
Ingredients

Civica and Thermo Fisher join forces to manufacture drugs in short supply

Thermo Fisher has agreed to produce Civica-owned Abbreviated New Drug Applications to secure the manufacture of certain essential medications
Ingredients

New microbiome specialist raises $82m and partners with Thermo Fisher

Arranta Bio will have access to Thermo Fisher’s full suite of products and services and will provide materials to Thermo Fisher for use in gene therapy production
Ingredients

Alfa Aesar joins Thermo Fisher Scientific

Johnson Matthey completes the £256m transaction to sell its research chemicals business to US life science supplier
Ingredients

Johnson Matthey agrees sale of research chemicals business Alfa Aesar

Subject to typical preclosing conditions, the transaction is expected to be completed by the end of 2015
Subscribe now